25-July-2019: The global cancer/tumor
profiling market size is expected to reach USD 21.08
billion by 2025, exhibiting a CAGR of 8.8%, according to a new report by Grand
View Research, Inc. Rising research in the application of omics sciences in
cancer detection is anticipated to influence market growth.
Technological
advances in biotechnology have allowed for deeper insights into metabolism and
gene expression. These have accelerated the application of advanced techniques
such as metabolomics and epigenetics in cancer screening and detection. Thus,
demand for cancer tumor/profiling (CTP) techniques is anticipated to witness
lucrative growth with the expansion of downstream applications.
Cancer tumor
profiling is a potential procedure through which cancer can be detected and
studied further to identify the stage, metabolism, and changes in morphology of
the tumor. This aids in routine diagnostics as well as therapeutic
decision-making. Tumor profiling has significant importance in developing
therapies aimed at a specific individual, based on the severity of ailment and
genomic build up of the individual.
Enhanced detection
and sequencing techniques such as NGS and in-situ hybridization can help speed
up the cancer tumor profiling process and are estimated to gain much traction
over the coming years. Their high adoption is attributive to accelerated speed
in gaining results with minimum resources and greater accuracy.
In
depth research report on Cancer/Tumor Profiling Market
Further key findings from the report suggest:
·
Personalized cancer medicine is expected to be the most
lucrative application segment for CTP adoption. The segment is expected to fuel
exhibit a CAGR of over 9.0%
·
Owing to difference in usage of and interdependency of
functional information from genomic, epigenomic, and metabolomic analysis of
cancer cells, it can be expected that these technology segments will grow in
tandem with each other and exhibit lucrative growth over the forecast years
·
Asia Pacific is projected to witness substantial growth over
the next decade owing to various developments across major economies, with
increased focus of dominant players in emerging economies as well
·
Key players include Illumina, Inc.; Qiagen N.V.; Neogenomics
Laboratories Inc.; HTG Molecular Diagnostics, Inc.; Genomic Health Inc.; Caris
Life Sciences Helomics Corporation; Nanostring Technologies; Oxford Gene
Technology; Ribomed Biotechnologies, Inc.; Personal Genome Diagnostics;
GenomeDX; Guardant Health; and Foundation Medicine.
Grand View Research
has segmented the global cancer/tumor profiling market on the basis of
technology, technique, application, and region:
Cancer/Tumor Profiling Technique Outlook (Revenue, USD
Million, 2014 - 2025)
·
Genomics
·
Proteomics
·
Metabolomics
·
Epigenetics
Cancer/Tumor Profiling Technology Outlook (Revenue, USD
Million, 2014 - 2025)
·
Sequencing Techniques
·
Next-generation Sequencing
·
Sanger Sequencing
·
Pyro Sequencing
·
In Situ Hybridization
·
Immunohistochemistry
·
Quantitative PCR
·
Microarray
Cancer/Tumor Profiling Application Outlook (Revenue, USD
Million, 2014 - 2025)
·
Personalized Cancer Medicine
·
Oncological Diagnostics
·
Research
·
Cancer Research
·
Biomarker Discovery
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment